An Open-Label, Non-Comparative Trial To Evaluate The Safety, Efficacy And Pharmacokinetics Of FASLODEX (Fulvestrant) In Girls With Progressive Precocious Puberty Associated With Mccune Albright Syndrome

Trial Profile

An Open-Label, Non-Comparative Trial To Evaluate The Safety, Efficacy And Pharmacokinetics Of FASLODEX (Fulvestrant) In Girls With Progressive Precocious Puberty Associated With Mccune Albright Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Precocious puberty
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms FMAS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Jul 2016 This trial has been completed in Germany as per European Clinical Trials Database record.
    • 19 Jul 2016 This trial has been completed in Germany as per European Clinical Trials Database record.
    • 02 May 2014 New source identified and integrated(ClinicalTrial.gov ;NCT00278915).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top